Tonsil carcinoma

Summary

Tonsil carcinoma (MONDO:0021337) is a cancer and 10 clinical trials. Top therapeutic interventions include trastuzumab botidotin. A subtype of tonsil cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tonsil carcinoma
Mondo ID	MONDO:0021337
NCIT	C4825
SNOMED CT	274085008
UMLS	C0558355
MedGen	107535
GARD	0027895
Anatomy (UBERON)	UBERON:0002372
Is cancer (heuristic)	yes

Also known as: cancer of the tonsil · cancer of tonsil · carcinoma of the tonsil · carcinoma of tonsil · tonsil cancer · tonsil carcinoma · tonsillar cancer · tonsillar carcinoma

Disease family

This is a subtype of tonsil cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › Waldeyer’s ring cancer › tonsil cancer › tonsil carcinoma

Related subtypes (3): tonsillar pillar cancer, tonsillar fossa cancer, tonsillar lymphoma

Subtypes (1): tonsillar squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04277858	PHASE2	RECRUITING	Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
NCT04870762	PHASE2	RECRUITING	Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
NCT03602079	PHASE1/PHASE2	COMPLETED	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03829033	Not specified	RECRUITING	Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.
NCT05904327	Not specified	ACTIVE_NOT_RECRUITING	Circulating Biomarkers in Oropharyngeal Cancers
NCT06902623	Not specified	RECRUITING	Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
NCT06915038	Not specified	RECRUITING	ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
NCT03226613	Not specified	COMPLETED	New Modalities for Detection of Oropharyngeal Cancer
NCT05696314	Not specified	COMPLETED	Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx
NCT05698667	Not specified	COMPLETED	Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRASTUZUMAB BOTIDOTIN	2	1
CHEMBL1510899	0	1